Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NFX-179 gel in cutaneous neurofibromas
NCT05005845Phase 2Completed
- Sponsor
- NFlection Therapeutics
- Start
- Sep 2021
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of NFX-179 Gel in cutaneous neurofibroma (cNF), neurofibromatosis type 1 (NF1), sponsored by NFlection Therapeutics. Started Sep 2021; status: completed.
02
Drugs
NFX-179 Gel
03
Conditions
cutaneous neurofibroma (cNF)neurofibromatosis type 1 (NF1)
Beyond the preview
Go deeper on NCT05005845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05005845.